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INTRODUCTION 
 
The first plant viruses to be developed as expression vectors in the early 1980s were those 
with DNA genomes (for reviews, see 42, 56). This was due to the fact that, at the time, only 
the DNA genomes could be manipulated and the technology for creating infectious cDNA 
copies of viruses with RNA genomes did not exist. However, the vast majority of plant 
viruses have genomes that consist of one or more strands of positive-sense RNA. These 
viruses infect a wide range of hosts and some can reach extremely high titres. Following the 
construction of the first full-length cDNA clones shown to be infectious (1), the past 25 years 
has seen a large number of RNA viruses developed as vectors for the expression of foreign 
sequences and other uses, such as gene silencing (10, 31, 42, 55, 56, 70).  
 
Many proteins have been successfully expressed with virus vectors and significant progress 
in vector design has been driven by the demands of this application. Generally developed 
with the expression of fluorescent marker proteins, RNA virus-based vectors have become a 
highly effective means of producing recombinant heterologous protein in plant tissue within a 
short time frame (28, 35, 44, 67). In addition to their use as vectors for the production of 
heterologous polypeptides and as gene silencing vectors, plant RNA viruses have also 
provided a source of particles for various applications. Virus capsids provide nano-scale 
particles with consistent size and shape, which can be exploited for a number of chemical and 
biological applications (72). For example, a number of systems make use of the repetitive 
geometry of plant virus capsids to present multiple copies of antigenic sequences, to increase 
their potential as a source of novel vaccines (10, 39, 58). Also, both wild type and genetically 
modified capsids of plant viruses are also being used as biotemplates for novel materials in 
nanotechnology (88). 
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Cowpea mosaic virus (CPMV) has borne witness to most of the aforementioned 
biotechnological uses of RNA viruses. The year 2009 marks the 50th anniversary of the first 
description of CPMV as a pathogen of cowpeas (Vigna unguiculata) in West Africa (13). As 
a result of its ease of propagation, high yield and the stability of the viral particles, CPMV 
rapidly became an object of intense scientific research. Early studies revealed the bipartite 
nature of the viral genome (7, 78), the structural similarities between CPMV and the animal 
picornaviruses (87) and the mechanism of gene expression (polyprotein processing; 53). 
Subsequent work resulted in the determination of the nucleotide sequences of both genomic 
segments (81, 43), a realisation of the genetic similarities between CPMV and picornaviruses 
(21), an atomic resolution structure of the virus particles (32, 33), and the creation of 
infectious cDNA clones (16, 25, 84). A crucial step for the development of practical CPMV-
based expression systems was the creation of vectors that could be inoculated by 
agroinfiltration (38), and this approach is now the method of choice for introducing CPMV-
based constructs into plants. 
 
This review covers the development of CPMV vectors since their first use as an epitope 
display platform in the early 1990s. The first plant virus to be successfully developed for this 
purpose (59, 77), CPMV virions continue to find many uses in bio-nanotechnology (20, 73). 
Through various incarnations as replicating viral vectors for polypeptide expression (9, 24, 66, 
82) and the successful production of a number of pharmaceutically relevant proteins (46, 47, 
49, 51, 65), investigation of limitations imposed by CPMV biology have yielded 
technological advances. Very recent developments have seen an extremely high-level 
expression system based on non-replicating CPMV sequences (67) being used to generate 
CPMV capsids devoid of RNA, thereby allowing CPMV capsids, which is where the 
biotechnology of CPMV began, to be exploited in novel ways.  
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COWPEA MOSAIC VIRUS – THE BASICS 
 
Cowpea mosaic virus (CPMV) is the type member of the Genus Comovirus in the family 
Comoviridae. It infects a number of legume species and grows to particularly high titres in its 
natural host, cowpea (Vigna unguiculata). It also infects the experimental host, Nicotiana 
benthamiana. The genome of CPMV consists of two separately encapsidated positive-strand 
RNA molecules of 5889 (RNA-1) and 3481 (RNA-2) nucleotides, both of which are required 
for infection. Both RNAs are polyadenylated and possess a small protein (VPg) covalently 
linked to their 5’ termini. The RNAs each contain a single open reading frame and are 
expressed through the synthesis and subsequent processing of precursor polyproteins (Fig. 
1a). RNA-1 encodes proteins involved in the replication of viral RNAs and polyprotein 
processing, including the RNA-dependent RNA polymerase, a helicase, the 24K proteinase, 
and a proteinase cofactor. RNA-2 encodes proteins essential for cell to cell movement and 
systemic spread, namely, the 48K movement protein and the two coat proteins, large (L) and 
small (S). Initiation at an upstream in-frame AUG results in a protein, the 58K protein which 
shares most of its sequence with 48K protein apart from an N-terminal extension. Further 
details of the molecular genetics of CPMV can be found in Goldbach and Wellink (23). The 
virus particles are composed of sixty copies each of the L and S coat proteins arranged with 
icosahedral symmetry (Fig 1b and c), and the particle structure is known to atomic resolution 
(32, 33). Particle formation is essential for the virus to spread both locally and systemically 
within plants (85) and for its transmission by its beetle vectors. 
 
CPMV AS A PEPTIDE-PRESENTATION SYSTEM 
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The initial motivation for using CPMV as platform to express peptides was the observation 
that the presentation of multiple copies of short antigenic peptides (epitopes) on the surface of 
a macromolecular carrier protein often enhances the immunogenicity of such peptides (41). 
Because of this, a number of systems, including CPMV, have been developed in which 
epitopes were genetically fused to self-assembling macromolecules, such as viruses, with the 
objective of creating novel vaccines. The ability of CPMV to grow to high titres in plants, the 
robustness of its particles and its lack of infectivity in mammalian cells made CPMV an 
attractive candidate for use as an epitope presentation system. Knowledge of the detailed 
three-dimensional structure of the particle allowed potential sites for the insertion of foreign 
peptides to be identified and the availability of infectious cDNA clones enabled the necessary 
genetic changes to be made. Thus CPMV became the first plant virus to be successfully 
developed as a peptide presentation platform (26, 40, 59, 77). Since the original reports 
describing the construction of chimaeric viruses, a large variety of epitopes have been 
expressed on the surface of CPMV particles. In most cases, the foreign sequence has been 
inserted into the most exposed loop of the virus surface, the βB-βC loop of the S protein, 
resulting in the display of 60 copies of inserted peptide on the surface the particle (Fig. 1a-c). 
Other sites, such as the βC’-βC” loop of the S protein and the βE-αB loop of the L protein, 
have also been used successfully (5, 14, 75, 57). Provided the inserted peptide is less than 40 
amino acids and has a pI below 9.0 (57) the yields of modified particles are generally similar 
to those obtained with wild-type CPMV (up to 1mg of particles per gram of infected leaf 
tissue). When purified virions were analysed by SDS-polyacrylamide gel electrophoresis, 
coat proteins of the appropriately increased size were observed. However, additional, smaller 
proteins, not seen with wild-type virus, were also routinely observed. These proteins arise 
through a proteolytic cleavage event near the carboxy-termini of the inserted sequence, which 
appears to be position-, rather than sequence-, dependent (75, 76). This cleavage does not 
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immediately result in the loss of the epitope from the surface of the virion but does lead to it 
being anchored at only its N-terminus (34); however, proteolytic trimming of the peptide can 
subsequently occur, leading to the loss of most, if not, all of the insert (N. Montague and G.P. 
Lomonossoff, unpublished data).  
 
A number of CPMV-based chimaeras have been subjected to immunological analyses. Where 
appropriate antisera were available, detection of the inserted epitope on the modified coat 
protein subunits was straightforward (59, 77), demonstrating the antigenicity of the chimaeric 
particles. To demonstrate that the particles are capable of raising an immune response against 
the presented peptide, purified virus particles have been administered to experimental animals, 
usually by intramuscular injection, followed by assessment of the properties of the resulting 
antisera. The first CPMV chimaera, and indeed, the first modified plant virus particle, to be 
assessed for the immunogenicity of a foreign peptide contained a 14 amino acid epitope (the 
NIm1A site) from VP1 of  Human rhinovirus 14 (HRV-14). The modified particles proved 
capable of raising specific antibodies against the insert when supplied parenterally to rabbits 
(59). Subsequently, a number of chimaeras expressing epitopes from a variety of pathogens 
have been analysed for their ability to raise specific antibodies, culminating in the 
demonstration that a chimaera displaying a 17-amino acid epitope from the major capsid 
protein of mink enteritis virus (MEV) could protect mink or dogs against challenge with the 
pathogen (15, 30). This work provided first example of plant-produced vaccine, albeit an 
experimental one. Since then, protective immunity has been generated in several animal 
species against a number of pathogens, both viral and bacterial. A summary of the results 
obtained from these types of experiments are shown in Table 1. 
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An additional attractive feature of using CPMV to present epitopes was the fact that the 
conditions for crystallisation of the virus were well established, potentially allowing 
crystallographic analyses of the structure of presented peptides to be undertaken. That this 
was a practical proposition was demonstrated by the crystallisation and structural analysis of 
the first CPMV chimaera expressing the NIm-1A site of HRV-14 (34; Fig. 1c). The NIm-1A 
sequence was found to adopt an extended conformation on the virus surface and displayed 
high mobility, which was attributable to the freedom of movement resulting from the 
cleavage at the C-terminus of the peptide. This was in marked contrast to the convoluted 
structure that the NIm-1A epitope adopts on the surface of HRV-14 itself and probably 
explained why antisera raised against this chimaera could bind to denatured HRV-14 VP1 but 
not intact HRV-14 particles. In an attempt to correlate the structure and mobility of the NIm-
1A epitope with the type of antibodies elicited, a series of chimaeras was produced with the 
sequence inserted in different positions on the CPMV surface (75). Only when the mobility 
of the NIm-1A peptide was restricted by preventing cleavage at the C-terminus of the epitope 
were antisera obtained that could bind to intact HRV-14 particles.  
 
Though the initial motivation for using CPMV particles to present peptides was to create 
novel vaccines, the same technology has recently been used for applications in 
nanotechnology.  The observation that certain peptide sequences can stimulate the deposition 
of specific inorganic compounds led to an investigation as to whether CPMV-based 
chimaeric virus technology could be adapted for the templated production of nanoparticles. 
By incorporating specific peptides on the virus surface, it was demonstrated that either silica 
or an iron-platinum alloy could be deposited on the virus surface (71, 74). These experiments 
represent but a small fraction of the many investigations into the use of virus particles, 
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including CPMV, in nanotechnology. However, research in this field has been reviewed 
extensively recently (73) and will therefore not be discussed further in this review.  
 
CPMV AS A GENE EXPRESSION SYSTEM 
 
Fully functional replicating vectors 
CPMV-based systems for the expression of whole genes have so far focussed exclusively on 
modifying the sequence of RNA-2 and co-inoculating the vector constructs with unmodified 
RNA-1 to provide polyprotein processing and viral replication functions. The primary reason 
for this is that increasing the size of RNA-2 above its normal length of 3.5kb, at least as far as 
the size of RNA-1 (6kb), should not affect its encapsidation and should therefore allow 
systemic spread of the modified virus. In addition, it has proved extremely difficult to make 
extensive modifications to RNA-1 without destroying virus viability. Two main approaches 
have been taken for the creation of autonomously replicating RNA-2-based expression 
systems, both of which have been assessed by the expression of the green fluorescent protein 
(GFP) from Aequorea victoria. 
 
The first published attempt to express a foreign protein from a CPMV-based vector used a 
gene replacement strategy that saw the exchange of most of the coat protein-coding region of 
RNA-2 with the sequence of GFP (82). Release of GFP was achieved by processing at the 
natural 48K/L junction, leaving 29 amino acids from the L protein fused to its amino 
terminus (Figure 2a). Although this construct was replicated by RNA-1 and GFP could be 
detected in individual cells, no infection was generated since no capsid proteins were 
produced. Systemic infection and GFP expression was achieved by co-inoculation with a 
complementary RNA-2 construct lacking the 48K movement protein, which supplied a 
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source of coat proteins (Figure 2a). This approach effectively created a tripartite virus and, 
therefore, was the first deconstructed plant virus vector. However, after several passages, 
expression of GFP was lost and RNA analysis showed that recombination had occurred 
between sequences which were present in both of the defective RNA-2 molecules. 
 
The second strategy used for protein expression was that of gene addition. In one format, a 
series of constructs was created in which the sequence encoding GFP was inserted between 
gene products of RNA-2 such that the full complement of viral genes was maintained (24, 82). 
To achieve release of GFP from the polyprotein, it was flanked by duplicated Q/M cleavage 
sites that would be recognised by the 24K proteinase from RNA-1 (Figure 2b). Although 
these vectors could spread systemically and expression levels of the released GFP reached 1-
2% of total soluble protein (24), the duplicated cleavage sites resulted in the released GFP 
having N- and C-terminal extensions. The presence of these additional amino acids is of 
particular concern in relation to the production of recombinant pharmaceuticals where close 
to, if not completely, authentic protein is required. Attempts to reduce the size of these 
sequences by minimising the size of the cleavage sites, resulted in inefficient processing and 
limited movement of the virus. The use of longer duplications, while giving effective 
processing, resulted in a higher frequency of homologous recombination and, therefore, loss 
of the insert and reversion to wild-type virus. The problems of the presence of additional 
sequences on the expressed protein and the genetic instability of the vectors have limited the 
use of the constructs to intracellular localisation studies (48). 
 
As an alternative to the use of duplicated 24K proteinase sites to achieve post-translational 
release of an inserted sequence, a number of RNA-2-based constructs have been produced 
which enable co-translational release via the action of the 2A catalytic peptide from foot-and-
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mouth-disease virus (FMDV). Incorporation of a 2A sequence, which can be as short as 16 
amino acids, between two proteins leads to an efficient co-translational separation of nascent 
polypeptides (18, 64); the use of such a sequence to achieve processing obviates the need to 
duplicate CPMV sequences and hence has advantages in terms of the genetic stability of 
constructs.  Cleavage at a 2A site occurs between the last to amino acids of the sequence, 
resulting in the N-terminal product having all but one of the 2A amino acids attached to its C-
terminus, while the C-terminal product has only an additional N-terminal proline. 
 
Initially, the 2A sequence was substituted for the one of duplicated proteinase site at either 
the N- or C-terminal side of the GFP sequence inserted between the 48K movement protein 
and L coat protein sequence in RNA-2 (Figure 2c). Only when the 2A sequence was inserted 
at the C-terminal side of the GFP insert were the constructs capable of efficient systemic 
spread in plants. This was probably a result of the 2A-mediated cleavage leaving a 16 amino 
acid extension on the C-terminus of the 48K movement protein when it is inserted to the N-
terminal side of the GFP sequence, with negative effects on the correct functioning of the 
movement protein. However, when the 2A sequence was positioned to the C-terminal side of 
the GFP sequence, most of the 2A peptide remained fused to the C-terminus of GFP. Though 
this does not interfere with the movement of the virus, it does have consequences for the 
authenticity of the expressed protein. In addition, because of the incompleteness of the 
cleavage mediated by the 2A sequence used, approximately 1 in 6 of the L subunits carried 
GFP fused to their N-termini and these fusion proteins can be incorporated into virus particles 
(24).  
 
Subsequently, GFP was fused to the C-terminus of the S protein via the 2A sequence (Figure 
2d). The resulting recombinant virus was able to systemically infect cowpea plants and 
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expressed GFP at approximately 1% of total soluble protein with less than 10% of GFP 
remaining fused to the S coat protein (24). A particular advantage of this approach is that the 
inserted sequence (in this case GFP) possesses only the single additional proline residue at its 
N-terminus and an authentic C-terminus. The co-translational nature of the 2A-mediated 
cleavage means that the C-terminal product can be directed to the plant secretory pathway by 
the inclusion of appropriate targeting sequences. Since the leader peptide is cleaved off 
during such targeting, the N-terminal proline left by the 2A-mediated cleavage is lost.  Thus, 
this full-length RNA-2-based construct was further developed into a practical vector for 
protein expression (CPMV NS-1) by modifications which permitted the one-step replacement 
of the sequence of GFP by any gene of interest and the use of agroinfiltration to initiate an 
infection (36) 
 
Pharmaceutical protein expression with CPMV NS-1 
Both Small Immune Proteins (SIPs) and full size antibodies have been expressed in plants 
from the autonomously replicating CPMV NS-1 vector. The SIPs consisted of single-chain 
antibody specific for transmissible gastroenteritis virus (TGEV) linked to either the ε-CH4 
domain from human IgE (ε-SIP; 49) or the α-CH3 domain from human IgA (α-SIP; 2) to 
promote dimerisation. The expressed molecules could neutralise TGEV in tissue culture and 
extracts from cowpea leaves inoculated with the CPMV-based vectors fed to piglets protected 
the animals against challenge with TGEV (49). Thus the crude leaf extracts could potentially 
be used to passively immunise newborn animals against TGEV. Subsequently, the production 
of a full-length IgG was achieved by co-inoculating separate CPMV NS-1 constructs 
containing the heavy and light chains of the blood group typing IgG, C5-1, in the presence of 
RNA-1 (65). In the above studies, all the antibody constructs were directed to the secretory 
pathway by positioning a native mammalian signal peptide between the 2A sequence and 
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immunoglobulin chain. Furthermore the antibodies could be retained within the endoplasmic 
reticulum with the use of a C-terminal HDEL or KDEL sequence, resulting in increased 
levels of accumulation.  
 
The ability of vectors based on CPMV to allow the simultaneous synthesis of proteins from 
multiple RNA-2 molecules in co-inoculated tissue, as is required for the production of a full-
sized antibody, is probably a consequence of the bipartite nature of the virus. This stands in 
contrast to the situation when vectors based on monopartite viruses are used. For example, 
the use of multiple constructs based on TMV to express different proteins results in 
segregation of the expression of each protein in agro-infiltrated tissue (22). This exclusion 
phenomenon can also affect foreign protein expression from some combinations of different 
monopartite viruses (17).  
 
In addition to the production of antibodies, CPMV-NS-1 has been used to express the 
hepatitis B virus core antigen (HBcAg), which was shown to self-assemble into core-like 
particles in cowpeas (47). HBcAg has a demonstrated potential to significantly enhance the 
immunogenicity of epitopes displayed on its surface and is, in itself, a potential source of 
novel vaccines (12, 60). Thus, autonomously replicating vectors based on CPMV have 
displayed the ability to produce pharmaceutically valuable polypeptides including those 
requiring glycosylation, and therefore, targeting to the secretory pathway. However, the 
inclusion of targeting sequences at the N-terminus of the inserted protein can have 
unpredictable consequences on the replication of the resulting RNA-2 constructs (L. 
Nicholson and G.P. Lomonossoff, unpublished data). 
 
Insert Side Bar: Non-coding sequences as encapsidated mimics 
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Replicating deleted versions of RNA-2 
Though clearly able to direct the expression of biologically active molecules, the use of 
CPMV vectors based on full-length RNA-2 molecules has a number of disadvantages. Such 
vectors produce infectious virus particles which are capable of spreading not only within a 
plant but between plants. Though this ability could be considered to be advantageous, 
especially where large amounts of plant material expressing the desired protein are required, 
it raises concerns about undesirable environmental spread.  Moreover, it has transpired that 
the ability to spread systemically is less useful than originally thought, as an inserted 
sequence tends to be lost when such spread occurs (49) and co-inoculated constructs tend to 
segregate in systemically infected tissue (65). Thus, in reality, only inoculated leaves have 
been used as the source of the expressed protein. Therefore, elimination of the ability to 
spread systemically by creating vectors based on defective versions of RNA-2  has the 
advantage of bio-containment with little penalty in terms of the amount of material that can 
be produced, provided that a highly efficient method of inoculation, such as agro-infiltration 
is used. Furthermore, reducing the size of the RNA should have advantages in terms of the 
maximum size of insert that can be stably expressed.    
 
To develop a system based on a defective version of CPMV RNA-2, most of the RNA-2 
coding sequence was removed, leaving only the 5´and 3´ sequences previously identified as 
being required for RNA-2 to be replicated by RNA-1 (63). To optimise the design of the 
vector, a series of deleted versions of RNA-2 (delRNA-2) was created in which the sequence 
of GFP was flanked by three different lengths from the 5’ region of RNA-2 and the complete 
3’ untranslated region (UTR). The three constructs were designed to initiate translation of 
GFP at AUG161 (the initiation codon for the 58K protein), AUG512 (the initiation codon for 
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the 48K protein) or AUG524 (the next in-frame AUG) of the RNA-2 sequence giving rise to 
constructs 5’-3’-GFP; 1-GFP and 2-GFP, respectively (Figure 2e; 9). Replication of 1-GFP 
and 2-GFP, but not 5’-3’-GFP, was observed when the constructs were co-infiltrated into N. 
benthamiana leaves in the presence of RNA-1 and a suppressor of gene silencing. 
Furthermore enhanced levels of GFP fluorescence were observed in the case of the 1-GFP 
and 2-GFP, but not the 5´3´-GFP construct, when RNA-1 and a suppressor were supplied. 
These results are consistent with the polymerase encoded by RNA-1 being able to replicate 
only versions of RNA-2 when the sequence between AUG161 and AUG512, as well as the 
5´UTR, is present (25, 63, 79). For all subsequent research, delRNA-2 constructs based on 
the design of 1-GFP (initiation at 512) have been used. 
 
Pharmaceutical protein expression with replicating delRNA-2 
The usefulness of the delRNA-2 system has been demonstrated through the successful 
expression of pharmaceutically active proteins. In the first instance, delRNA-2 constructs 
containing the sequences of either the H or L chain IgG C5-1 were co-infiltrated into N. 
benthamiana leaves in the presence of RNA-1 and the heterologous potyviral silencing 
suppressor HC-Pro (6). Fully formed IgG molecules were obtained at levels (74mg/Kg wet 
weight leaf tissue) which substantially exceeded those obtained when the same antibody was 
expressed using full-length RNA-2 vectors (19mg/Kg wet weight leaf tissue; 65). As well as 
the expression of antibodies, the delRNA-2 approach has also been used successfully to 
express the core antigen of hepatitis B virus (HBcAg; 46) and the enzyme human glutamic 
acid decarboxylase (hGAD-65; M.C. Canizares, L. Avesani and G.P. Lomonossoff, 
unpublished data), which has potential applications in preventing Type I diabetes .   
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In addition to giving higher levels of protein expression than full-length RNA-2 vectors in 
inoculated tissue, the delRNA-2 system removes the possibility of modified viral particles 
spreading in the environment. Recent results have shown that even in the presence of wild-
type RNA-2, the RNA from construct 1-GFP is not trans-encapsidated, indicating that even 
accidental coinfection with wild-type CPMV would not lead to the spread of the foreign 
sequence (F. Sainsbury and G.P. Lomonossoff, unpublished data).  
 
Combined transgene/viral vector system 
Despite the high levels of expression obtained using delRNA-2 vectors, the use of defective 
viruses suffers from the limitation that expression is restricted to inoculated tissue. This 
disadvantage can be overcome by simply increasing the amount of tissue that is infiltrated 
using a technique such as the vacuum infiltration of whole plants. However, an alternative 
would be a system in which the replicating construct is produced in all cells of a plant from a 
transgene, and such a system has been developed for CPMV (9).  
 
The first stage in the development of a CPMV transgene/virus vector expression system was 
to check if an integrated full-length copy of RNA-2 containing a foreign gene could be 
replicated by supplying the RNA-1. To this end, N. benthamiana was transformed with a full-
length version of RNA-2 containing GFP (CPMV NS-1). The resulting plants were identical 
in appearance to non-transgenic N. benthamiana and showed no detectable green 
fluorescence. When these plants were agroinfiltrated with RNA-1, they developed localized 
green fluorescence around the area of inoculation and this fluorescence subsequently spread 
beyond the inoculated leaves to give patches on the stems and on the upper, uninoculated 
leaves. In addition, when the plants transformed with CPMV NS-1 were crossed with an 
RNA-1-containing transgenic line, the resulting plants showed a high level of GFP 
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production throughout (9). These results showed that RNA-1 supplied either exogenously or 
expressed from a transgene is capable of replicating a transgene-derived RNA-2 molecule 
containing a foreign gene. To prevent the production infectious virus, the system was 
improved by adapting it for use with delRNA-2 constructs. When RNA-1 alone was supplied 
by agroinfiltration to plants transgenic for the three delRNA-2 constructs described above, no 
replication of any of the transgene-derived delRNA-2 molecules could be detected.  However, 
when a suppressor of silencing was simultaneously supplied, either in the form of the natural 
CPMV suppressor encoded by full-length RNA-2 (11, 37) or HC-pro, an increase in the 
levels of fluorescence was seen in the case of the 1-GFP and 2-GFP, but not the 5´3´-GFP, 
transgenic plants, These results are consistent with the conclusion that enhanced GFP 
expression requires replication of the transgene-derived mRNA, which can only occur when 
both RNA-1 and a suppressor of silencing are present simultaneously.  
 
To produce a system in which delRNA-2 molecules can be expressed and replicated 
throughout an entire plant, N. benthamiana transgenic for both CPMV RNA-1 and HC-Pro 
were produced. These were shown to be capable of supporting the replication of 
agroinfiltrated 1-GFP and of giving high levels of GFP expression. Furthermore, when the 
RNA-1 and HC-Pro double transgenic plants were crossed with those transgenic for 1-GFP, 
the progeny containing all three transgenes were brightly fluorescent throughout the plant, 
whereas those transgenic for just HC-Pro and 1-GFP were not (9). The level of GFP 
expression enhancement over plants transgenic for 1-GFP alone was estimated to be at least 
10-fold and the presence of negative-strand delRNA-2 in the plant tissue showed this was 
associated with replication of the transgene-derived 1-GFP RNA by RNA-1. 
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The combined transgene/virus system based on delRNA-2 has several advantages in addition 
to that of biocontainment. Among these is the fact that every cell in a transgenic plant will 
contain a “master copy” of the foreign sequence embedded in the delRNA-2 construct. This 
should lead to an enhancement in the genetic stability of heterologous sequences since 
propagation of the foreign sequence throughout the plant will not rely on successive rounds 
of RNA viral replication. This, in turn, may permit the stable expression of larger proteins 
than is possible when delRNA-2 sequences are used in a transient format. In addition, it 
should be possible to produce larger amounts of plant tissue compared with when the 
transient system based on agroinfiltration is used.  On the downside, the production of lines 
of transformed plants is a considerably longer process than transient expression via 
agroinfiltration. 
 
Hyper-translatable RNA-2 5’ UTR 
The 5’ region of CPMV RNA-2 has a somewhat complicated structure. Though most protein 
synthesis, which ultimately results in the production of the 48K movement protein, initiates at 
AUG512, some initiation occurs at the upstream, in-frame AUG at position 161, giving rise 
to the 58K protein. In addition there is a further upstream, out of phase AUG at position 115, 
which can potentially direct the synthesis of a 20 amino acid peptide (Figure 3a).  The 
method by which CPMV RNA-2 escapes the first-AUG rule (29) and initiates at both 
AUG161 and AUG512 is not clear but may involve a combination of leaky scanning and 
reinitiation. The AUG at 115 is known to initiate translation in vitro (86) although the 
resulting peptide has no known function. Preserving frame continuity between the AUGs at 
161 and 512 is required for replication of RNA-2, though the precise reason for this is unclear 
(25, 63, 79). 
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The need to preserve frame continuity between AUG 161 and 512 in order to retain the 
replication ability of RNA-2-based vectors complicates their construction. However, while 
the replication of delRNA-2 constructs is essential to achieve high levels of expression when 
the RNA-2-based mRNA is derived from a transgene (9), it is less important for transient 
expression since mRNA can accumulate to very high levels in agroinfiltrated tissue, 
particularly in the presence of a suppressor of silencing. With the goal of improving the ease 
of cloning, the necessity of maintaining frame continuity between AUG 161 and 512 for high 
level expression of foreign proteins from delRNA-2 in transient assays was investigated using 
variants of the construct 1-GFP (67). The continuity of reading frame between the AUG for 
GFP translation initiation and AUG161 was altered by adding nucleotides immediately 
upstream of AUG512. The effect of these changes was determined by agroinfiltrating the 
constructs into N. benthamiana leaves in the presence of the suppressor of silencing P19 (83) 
and assessing the level of GFP expression. Adding one or two nucleotides, so translation 
occurs from positions 513 and 514, reduced GFP expression relative to that which occurs 
when the AUG is at 512, while adding 3 nucleotides so translation occurred at position 515 
restored the expression to the original level (Figure 3b; F. Sainsbury and G.P. Lomonossoff, 
unpublished data). These observations suggest a dependency on frame continuity between 
AUGs 161 and 512 for translation to occur efficiently from AUG512. To investigate whether 
this dependency could be obviated, a series of mutants was constructed by systematically 
removing one or both of AUGs at 115 and 161 from each of three reading frame variants 
(Figure 3a). While removal of AUG115 (Δ115) led to a reduction of GFP expression from all 
reading frame variants, deletion of AUG161 (Δ161) led to a massive increase in GFP 
expression, which was further enhanced by the simultaneous elimination of AUG115 (Figure 
3b; 67). This great enhancement of expression levels, which was seen in all three reading 
frame variants, did not result from elevated mRNA levels but was due to the mRNA 
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molecules being “hyper-translated” relative to the wt leader. For this reason, the RNA-2 
leaders lacking either AUG161, or both AUG115 and AUG161, are referred to as the hyper-
translatable or HT leaders.  
 
 
Extremely high level protein expression easily and quickly 
The levels of foreign protein produced using the HT leaders far exceeded those achieved from 
replicating full-length or delRNA-2 vectors in transient expression studies. To exploit this 
phenomenon, a number of pharmaceutically relevant proteins have been expressed using the 
CPMV-HT system  They include approximately 1g per kg of agroinfiltrated tissue of 
assembled HBcAg particles (67), and up to 0.4g per kg of the human anti-human 
immunodeficiency vius IgG, 2G12 (68). The fact that these levels are attained without the 
need for viral RNA polymerase to amplify transcripts reduces the chance of mutations being 
introduced during replication. It could also extend the range of hosts which can be used 
beyond those species that support CPMV replication. 
 
The most recent development of the CPMV-HT expression system has seen the components 
of the system (the CPMV-HT expression cassette and the P19 sequence) placed onto a single 
vector for Agrobacterium-mediated delivery to plant cells. This was achieved by constructing 
a new binary vector backbone derived from pBINPLUS (80), which is based on the highly 
successful pBIN19 (3). The new pEAQ vectors are less than half the size of the parent 
plasmid while retaining all the essential components for efficient transient expression (68). 
Furthermore, the removal of reading frame dependency, necessary for replication and 
evidently adversely affecting translation (Figure 3b), has permitted the use of a multiple 
cloning site for direct insertion into the most effective CPMV-HT vector, pEAQ-HT. In 
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addition, it has been possible to construct pEAQ-HT variants that are compatible with the 
GATEWAY system of recombination-based cloning (68).  
 
The extremely high level expression of therapeutic proteins by CPMV-HT, achievable within 
a few days, has great potential for use in the high-throughput screening of vaccine candidates. 
Combined with the simplicity afforded by the pEAQ series of binary vectors, which permit 
one-step and optional high-throughput cloning, milligram quantities of foreign protein can be 
produced within 2 to 3 weeks of receiving a DNA sequence. This means that a significant 
number of target protein variants can be screened within a very short time-frame. 
 
GENERATION OF EMPTY CAPSIDS 
 
As previously mentioned, while the CPMV capsid-based technologies have enjoyed 
considerable successes, the range of applications has been restricted by the need to propagate 
the virus by the infection of plants. This means that viral particles must be fully competent 
for movement from cell-to-cell, placing limitations on sequences that can be successfully 
expressed on the particle surface (57). Furthermore, the particles must retain their ability to 
package the genomic RNA, as this is essential for the virus to move between cells. As a result, 
the majority of particles isolated from plants contain either RNA-1 or RNA-2 meaning that 
preparations remain infectious, raising biosafety issues. A further disadvantage is that, being 
full of RNA, the particles cannot be loaded with heterologous material. The CPMV-HT 
expression system has provided a means of producing CPMV capsids in plants without the 
need for infection, thereby overcoming these concerns and limitations.  
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To achieve capsid formation in the absence of infection, the sequence of the precursor of both 
the L and S coat proteins, VP60, was expressed in plants using pEAQ-HT. Processing to the 
mature L and S coat proteins was achieved by co-infiltration with either full-length RNA-1 
(to provide the 24K proteinase function) or just the 24K proteinase, also expressed from 
pEAQ-HT (Figure 4a; 69). In both cases efficient processing of VP60 to the L and S proteins 
was observed, and virus-like particles (VLPs), similar in structure to wild-type CPMV, could 
be purified from the inoculated tissue. Analyses of these VLPs showed that using RNA-1 to 
process VP60 resulted in the encapsidation of RNA-1 in a proportion of the VLPs (Figure 
4b,c). In contrast, using just the 24K proteinase to process VP60 results in the production of 
exclusively empty or eVLPs (Figure 4b,c). The fact that it is possible to produce preparations 
completely devoid of RNA demonstrates that, unlike some other plant virus-based VLPs (8), 
CPMV VLPs do not encapsidate host-derived RNA (69). 
 
The development of a method for the generation of eVLPs should prove very valuable to 
researchers developing technologies based on CPMV capsids. Previously, irradiation with 
ultraviolet light (30, 61) or chemical treatment (54) has been used to eliminate the infectivity 
viral RNAs. However, although addressing biosafety concerns, these processes risk altering 
the structural properties of the particles and do not actually remove the RNA from within the 
particles. An alternative approach has been to treat a natural population of CPMV at high pH, 
which results in the loss of RNA from the particles (52). However, as all these method make 
use of particles originally produced through the infection of plants, they do not address the 
limitations imposed by the need to maintain the ability of the capsids to assemble with RNA 
and move throughout the plant. In addition to alleviating biosafety concerns, the production 
of eVLPs via the CPMV-HT system no longer requires that the particles be able to package 
RNA or to spread between plant cells; they need only retain their ability to assemble. This 
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should greatly increase the range of mutations that it is possible to introduce on to the outer 
surface of coat proteins and will make it possible to modify the inner capsid surafce. As a 
result, these easily generated eVLPs should find use as nano-sized reaction vessels for 
chemical and bionanotechnological applications (20). This opens the possibility of combining 
internal modification/loading with exterior functionalisation, introduced genetically or 
chemically.  
 
CLOSING REMARKS 
 
With the use of the non-replicating CPMV-HT expression system to produce viral capsids, 
the use of CPMV in biotechnology appears to have come full circle. Through the 
development of a CPMV-based expression system, the promises of CPMV capsid-based 
technologies have been renewed by harnessing modified elements of the virus to generate a 
more useful version of itself. Thus, the “Ouroborus” that represents the development of 
CPMV-based expression strategies has breathed new life into some of the earliest 
technologies for which this versatile virus has been used. 
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ARTICLE COMPONENTS 
 
Keywords:  viral vector, molecular farming, epitope display, vaccine, bionanotechnology, 
virus-like particles 
 
Abstract: 
In the 50 years since it was first described, Cowpea mosaic virus (CPMV) has become one of 
the most intensely studied plant viruses. Research in the past 15-20 years has shifted from 
studying the underlying genetics and structure of the virus, into focussing on ways in which it 
can be exploited in biotechnology. This work led first to the use of the virus particles to 
present peptides, through the creation of a variety of replicating virus vectors, and thence, to 
the development of a highly efficient protein expression system that does not require viral 
replication. Finally, the circle has been completed by the use of the latter system to create 
empty particles for peptide presentation and other novel uses. Thus, the history of CPMV in 
biotechnology can be likened to an “Ouroborus”, an ancient symbol depicting a snake or 
dragon swallowing its own tail, thus forming a circle. 
 
Terms/Definitions:  
 Epitope display – The presentation of antigenic peptides on the surface of a carrier 
molecule. 
 Bipartite – Having a genome consisting of two molecules of nucleic acid.  
 Agroinfiltration – A method of delivering DNA to plant nuclei by pressure-infiltrating 
Agrobacterial suspensions 
 Ouroborus – a symbol, in the form of a snake or dragon swallowing its own tail that 
represents something constantly re-creating itself. 
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Acronyms list:  
 GFP – Green Fluorescent Protein from the jellyfish, Aequorea victoria 
 2A – co-tranlationally cleaved peptide from foot and mouth disease virus 
 HBcAg – Hepatitis B core Antigen 
 Ig – Immunoglobulin 
 HT – Hyper-Translated 
 UTR – Untranslated Region 
 VLP – Virus-Like Particle 
 eVLP – Empty VLP  
 
Summary Points: 
1. In the 50 years since the first identification of CPMV, this simple and robust bipartite 
RNA virus has proved to be useful in many and varied areas of biotechnology. 
2. CPMV was the first plant virus to be developed as a peptide display system and a 
number of chimaeric particles displaying epitopes from pathogens have been shown 
to provide protective immunity. 
3. As a nanoparticle for which the structure is very well known, CPMV has attracted 
interest for medical and chemical applications. 
4. Replicating vectors based on CPMV have been used to produce a variety of 
pharmaceutically relevant proteins. 
5. The non-replicating CPMV-HT system provides a means of producing milligrams of 
recombinant proteins in plant tissue within days on a bench scale. 
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6. The efficient production of eVLPs through the use the CPMV-HT system will expand 
the range of genetically generated surface modifications which it is possible to 
introduce. 
7. The absence of RNA in eVLPs will enable the interior of the capsid to be modified 
and heterologous material to be loaded. Thus eVLPs have potential as reaction vessels 
or drug delivery vehicles. 
 
Future Issues: 
1. As with all plant-made pharmaceuticals, there will be significant regulatory hurdles to 
be overcome before any of the products made using the CPMV-based systems 
described in this review will be licensed for human or veterinary use. 
2. A particular issue that will need to be addressed is the batch-to-batch variation which 
may occur when transient expression systems, such as those described in this review, 
are used for pharmaceutical production. 
3. Even if all the regulatory hurdles are overcome, it will be necessary to demonstrate 
that the production of proteins using CPMV-based systems has significant advantages 
(eg. In terms of cost or quality of product) over other production systems.  
4. The non-competing nature of CPMV-HT expression vectors raises the possibility of 
producing protein complexes or mimicking metabolic pathways within plants. 
Exploration of the full-range of possibilities has only just begun. 
5. The availability, for the first time, of a source of empty CPMV capsids (eVLPs) 
which are not produced by infections, opens a whole new area of research into the 
potential uses of the virus.   
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Side Bar: 
Non-coding sequences as encapsidated mimics 
Though the majority of work on full-length RNA-2 vectors has concentrated on the 
expression of proteins, it is also possible to insert non-coding sequences between the C-
terminus of the polyprotein and the 3’UTR. Such sequences are packaged into RNA-2-
containing CPMV virions and are therefore, like the genomic RNAs, protected from nuclease 
degradation. As a result, particles harbouring the modified RNA-2 molecules, known as 
CPMV RNA mimics, can be used as in-tube internal controls in diagnostic real-time reverse-
transcription PCR (rRT-PCR) assays for the detection of RNA viruses (27). False negative 
results are clearly undesirable when screening for diseases and CPMV RNA mimics can be 
used to verify negative assay results by confirming the absence of rRT-PCR inhibitors from 
clinical samples. Moreover, primers pairs for diagnosis of multiple viruses may be 
incorporated into a single CPMV RNA mimic. 
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FIGURE LEGENDS 
 
Figure 1. CPMV as a peptide-presentation system. The B-C loop of the S coat protein 
(indicated by red arrows in a and b) is the most commonly used site for the insertion of 
foreign peptides. (a) Genome organisation of CPMV RNAs. ProC – proteinase co-factor; 
VPg – genome-linked protein; Pro – 24K proteinase;  48/58K - movement protein; L – large 
coat protein; S – small coat protein. (b) Ribbon diagram of the icosahedral asymmetric unit, 
consisting of the two domains of the large coat protein (cyan and green) and the small coat 
protein (dark blue). (c) Space-filling drawing of the CPMV capsid displaying an epitope from 
HRV-14 inserted into the B-C loop of the S protein shown in red; kindly provided by Dr. T. 
Lin and Prof. J.E. Johnson, The Scripps Research Institute, La Jolla, USA. 
 
Figure 2. CPMV as a polypeptide expression system. RNA-2-based vector improvement has 
been advanced by the development of systems compatible with agroinfiltration. (a) A gene 
replacement approach whereby the foreign sequence (GFP) replaces the coat proteins and 
systemic movement is restored by providing the appropriate sequences in a third construct. (b) 
A gene addition approach in which GFP is placed between duplicated 48K/L glutamine-
methionine (QM) cleavage sites. (c) A gene addition approach where duplication QM 
cleavage sites and the FMDV 2A sequence are used. (d) Full-length RNA-2 construct in 
which GFP is placed at the end of the open reading frame following the 2A catalytic peptide. 
(e) Series of deleted RNA-2 constructs where initiation of translation starts at AUG 161, 512, 
or 524. Grey arrow indicates CaMV 35S promoter, zig-zag indicates poly-A signal, and grey 
box indicates the nos terminator. 
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Figure 3. Expression from modified RNA-2 5’UTRs. The unusual translation strategy 
employed by CPMV RNA-2 was investigated using a series of 5’UTR mutants. (a) Schematic 
representation of the RNA-2 5’UTR variations each with three initiation site options for the 
translation of GFP from different reading frames. (b) Visualisation of GFP expression from 
5’UTR variants  in leaves 5 days after agroinfiltration using UV light.  
 
Figure 4. Production of CPMV eVLPs. CPMV-HT was used to produce CPMV capsids 
devoid of RNA by providing large amounts of the coat protein precursor, VP60, and the 24K 
proteinase. (a) Schematic representation of the constructs used to create VLPs. Grey arrow 
indicates CaMV 35S promoter, and grey box indicates the nos terminator. (b) Illustration of 
the different types of particles generated by the coexpression of various components as 
indicated, where RNA-2 + RNA-1 represents a natural infection. (c) Analysis of nucleic acid 
content of CPMV VLPs produced by different approaches using an ethidium bromide-stained 
agarose gel. Section (c) reprinted from reference 69, Copyright (2009), with permission from 
Elsevier. 
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Table 1. Immunological properties of CPMV chimaeras created by genetic modification of capsid genes 
 
Site of insertion Sequence inserted Immunological properties 
B-C loop 
S protein HRV-14 VP1 epitope 
Raises non-neutralising antibodies aginst HRV-14 (59, 
75) 
C’-C” loop 
S protein HRV-14 VP1 epitope Raises non-neutralising antibodies aginst HRV-14 (75) 
B-C loop 
S protein 
HIV-1 gp41 
Epitope 
(59,45) Raises neutralising antibodies aginst HIV-1 
(19) stimulates mucosal immune response in mice 
B-C loop 
S protein 
MEV VP2 
Epitope 
15) Protects mink against MEV (30) protects dogs 
against CPV (50) stimulates mucosal immune response 
in mice 
E-B loop 
L protein 
P. aeruginosa  
F protein epitope 
(5) Protects mice against infection with P. aeruginosa 
(4) stimulates mucosal immune response in mice 
B-C loop 
S protein 
S. aureus D2 domain of 
FnBN 
Protects rats against secondary infection by S. aureus 
(62) 
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